USPTO serial 87265335
EKOS PE ACCEL
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- EINSTEIN, MATTHEW T
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with EKOS PE ACCEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sara Citrowske
Sara Citrowske Boston Scientific CorporationOne Scimed PlaceMaple Grove, MN 55311UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Surgical apparatus and instruments; Medical apparatus and instruments for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma; Medical apparatus and instruments for use in the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma and software sold as a unit therewith; drug delivery apparatus and instruments, namely, ultrasonic medical apparatus; Drug delivery apparatus and instruments, namely, ultrasonic medical apparatus and software sold as a unit therewith; Drug delivery systems; surgical and medical apparatus and instruments for use in treatment of the circulatory system; Medical apparatus and instruments for use in the prevention and treatment of the circulatory system issues and conditions, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma; medical devices which use ultrasound to enhance drug delivery and medically activate drugs; catheters for delivery of drugs and fluids and controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus and controllers and power units therefor; catheters; parts and fittings for all the aforesaid goods | ACTIVE | — |
| 041 | Education services, namely, developing, arranging and conducting educational conferences and programmes and providing courses of instruction in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma and distribution of course material in connection therewith; training in the use and operation of medical devices, medical ultrasound apparatus and medical research apparatus and consultation relating thereto; educational services, namely, conducting live and online seminars, classes, workshops, conferences, lectures, panel discussions, and training programs in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma and distribution of course material in connection therewith; educational services, namely, providing non-downloadable webinars in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma and distribution of course material in connection therewith; provision of educational content, namely, providing on-line instruction in the fields of health care and medical diseases, disorders and related treatments and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma and distribution of course material in connection therewith; providing computer, electronic and on-line databases featuring information about medical education in the field of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and patient care; advisory services in the fields of medical education; educational services, namely, conducting live and online seminars, classes, workshops, conferences, lectures, panel discussions and training in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine; educational services, namely, providing non-downloadable webinars in the fields of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine and distribution of course material in connection therewith; non-downloadable electronic publications in the nature of teaching guides, instructional materials, brochures, and course books in the fields of healthcare, the use of pharmaceuticals and medical devices, medical research, surgery, medical science, medicine and in the fields of the prevention and treatment of circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusion, blood clots, vascular issues and conditions, and intracranial haemorrhages, cerebral haemorrhages, and hematoma; electronic on-line databases featuring information about medical education in the field of healthcare, pharmaceuticals, medical devices, medical research, surgery, medical science and medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 15, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 15, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 30, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 30, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 30, 2020 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Aug 30, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 30, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 12, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 11, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 23, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jul 23, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 8, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 6, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 6, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 6, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 31, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 29, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 29, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 29, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 25, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 23, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 23, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 23, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 3, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 1, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 1, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 1, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 6, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 12, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 12, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 22, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 9, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 9, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 9, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 9, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 9, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 6, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 6, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 6, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 16, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 15, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 15, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 15, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 1, 2017 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 31, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jan 12, 2017 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 15, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 15, 2016 | NWAP | NEW APPLICATION ENTERED | — |